BIO-TECHNE Corp (TECH)

Bio-Techne Corporation, a Minnesota corporation headquartered in Minneapolis and founded in 1976 as Research and Diagnostic Systems, Inc. (publicly traded since 1985, NASDAQ: TECH), develops, manufactures and sells life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide, operating in two segments. The Protein Sciences segment, roughly 72% of fiscal 2025 net sales, comprises the Reagent Solutions division (specialized proteins such as cytokines and growth factors, antibodies, small molecules, tissue culture sera and cell selection technologies, sold under brands including R&D Systems, Tocris Biosciences and Novus Biologicals, serving research, diagnostics, and cell- and gene-therapy customers, including cGMP-grade proteins, bolstered by investments like Wilson Wolf for cell culture devices) and the Analytical Solutions division (manual and automated protein analysis instruments and immunoassays, including automated western blotting and multiplex immunoassay platforms, under brands like R&D Systems and ProteinSimple, with some products FDA-cleared as in vitro diagnostics). Customers in this segment include academic and industry researchers, pharmaceutical and biotech companies, and contract research organizations, reached via direct sales in North America, Europe and China, a distribution agreement with Thermo Fisher Scientific, and third-party distributors elsewhere, with no single customer exceeding 10% of segment sales.

The Diagnostics and Spatial Biology segment, about 28% of fiscal 2025 net revenues, includes three divisions: Spatial Biology (Advanced Cell Diagnostics brand in-situ hybridization assays and, following the Lunaphore acquisition, the COMET instrument for hyperplex spatial protein/RNA detection), Molecular Diagnostics (Exosome Diagnostics liquid biopsy tests such as the ExoDx Prostate test, an exclusively licensed ExoTRU kidney transplant rejection test, and Asuragen-branded genetic carrier screening, oncology diagnostics and molecular controls), and Diagnostic Reagents (calibrators, controls and process-control products for hematology, blood chemistry, blood gases and coagulation, largely sold on an OEM basis to instrument manufacturers). This segment serves academic and pharmaceutical/biotech researchers, clinical laboratories, physicians (for the CLIA-certified, CE-marked ExoDx Prostate test), and diagnostic instrument manufacturers, primarily in North America, Europe and China, with distributors used elsewhere, and no customer represents 10% or more of segment sales. The company competes across a broad and fragmented set of global and niche competitors based on price, quality, performance, innovation, distribution and brand recognition, sources raw materials from numerous suppliers without material single-supplier dependency, ships most products quickly with minimal backlog, experiences some seasonality tied to academic schedules and patient scheduling patterns, and pursues growth through internal R&D (over 400 new products introduced in fiscal 2025) as well as strategic acquisitions and investments to expand its product portfolio and enter adjacent research, diagnostics and cell-and-gene-therapy markets.